ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
BioCryst Pharmaceuticals will restructure and focus on advancing its hereditary angioedema (HAE) and antiviral programs. The North Carolina-based company will cut 50% of its workforce, or 38 positions. The restructuring comes after setbacks in its peramivir and BCX5191 antiviral programs and a delay in its BCX4161 HAE program. Meanwhile, QLT, an ocular drug firm based in Vancouver, British Columbia, will cut 42% of its workforce, or about 30 employees. It eliminated 146 positions in July. QLT sold its Visudyne macular degeneration drug to Valeant Pharmaceuticals for $113 million in September. QLT’s remaining 38 employees will work on clinical development of synthetic oral retinoids.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter